Novel CXCR2 antibodies exhibit enhanced anti-tumor activity in pancreatic cancer
Open Access
- 8 March 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 185, 117966
Abstract
No abstract availableKeywords
Funding Information
- Korea Institute of Science and Technology (2E33310)
This publication has 54 references indexed in Scilit:
- Therapeutic inhibition of CXCR1/2: where do we stand?Internal and Emergency Medicine, 2023
- CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic targetCancer Communications, 2020
- Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseasesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- Erenumab: First Global ApprovalDrugs, 2018
- Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery StrategiesBioDrugs, 2018
- In vitro expression and analysis of the 826 human G protein-coupled receptorsProtein & Cell, 2016
- An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseasesBiotechnology Advances, 2013
- Construction of a Large Synthetic Human scFv Library with Six Diversified CDRs and High Functional DiversityMolecules and Cells, 2009
- CXCL8/IL‐8 and CXCL12/SDF‐1α co‐operatively promote invasiveness and angiogenesis in pancreatic cancerInternational Journal of Cancer, 2008
- Mapping of the Extracellular Binding Regions of the Human Interleukin-8 Type B ReceptorBiochemical and Biophysical Research Communications, 1997